ACN — Accenture plc

Sentiment is cautiously improving rather than outright bullish. Q3 FY26 EPS beat by $0.10, bookings stayed robust at $19.3B, and the stock has bounced more than 20% from its June lows. Still, ACN is down ~28% YTD, the analyst consensus is only a moderate Buy (36 Buy / 16 Hold / 1 Sell), and the AI-driven consulting-disruption debate keeps a lid on enthusiasm.

Revenue growth is stabilizing, not collapsing: Q3 FY26 revenue rose 5.6% YoY to $18.72B, a slight deceleration from Q2 FY26's 8.3% growth but consistent with a mid-single-digit trajectory. Operating margin expanded 20bps YoY to 17.0%, and diluted EPS rose to $3.80 from $3.49 (+8.9%). The clear outlier is Q4 FY25, when an $817M charge crushed operating margin to 11.7% and EPS to $2.25; excluding that one-off, margins have been stable and are now near the top of their historical 13%-17% band. TTM EPS of $12.78 is depressed by that charge; normalized trailing EPS is closer to $13.80.

Cheap by its own history. As of 2026-08-27, TTM P/E is 14.8x versus the 5-year average of 28.6x, and P/S is 1.57x versus 3.2x. Forward P/E is roughly 13.5x on consensus EPS of $13.86, or about 13.9x on FY26 guidance midpoint of $13.44. The 4.69% dividend yield is historically high for ACN. The balance sheet is not the problem—debt/equity is 0.26, the current ratio is 1.34, and free cash flow was positive in every quarter shown—so the cheap multiple is the market applying a genuine AI-disruption discount rather than a deterioration in reported fundamentals.

The price is discounting an earnings recession that the reported numbers do not yet show. TTM earnings are actually up (roughly $12.78 reported, ~$13.80 normalized versus FY25's $12.15), and management guided FY26 EPS to $13.38-$13.50. At $187, the market is applying only ~14x to a company generating 17% ROIC, negative accruals, and robust FCF. If AI fears are overdone, this is a re-rating opportunity; if they are correct, the low multiple is justified. The Q3 EPS beat and strong bookings tilt the near-term odds toward the former, but the market is right that the old billable-hours model faces structural questions.

As of 2026-08-27, RSI(14) is 65.0—strong momentum but not yet overbought. Price is 5.6% above the 20-day SMA and 21.0% above the 50-day SMA, but still 8.4% below the 200-day SMA, so the longer-term trend remains down. This is a powerful oversold bounce, not a confirmed new uptrend. Chasing here at $187 is late; a pullback toward the 20-day or 50-day area would offer better risk/reward for new buyers.

• Generative AI anxiety is compressing the entire IT services sector multiple on fears that AI will commoditize billable-hour consulting.
• CIOs remain budget-disciplined, with spend rotating toward AI, cloud migration, and cybersecurity rather than legacy systems integration.
• The U.S. federal business is dragging FY26 local-currency growth by roughly 1%.
• Accenture is deploying a ~$9B M&A framework (Dragos, runZero, NetRise, COMWARE) to reposition toward OT security and AI platforms.
• A higher-for-longer discount-rate environment has forced multiple normalization from the 28x historical average to ~14x.

• Q4 FY26 earnings on October 1, 2026—especially initial FY27 revenue and EPS guidance.
• Conversion of AI/GenAI bookings into recognized revenue; data/AI partner bookings reportedly more than doubled YoY.
• Integration and scaling of recent OT-security acquisitions (Dragos, runZero, NetRise) and COMWARE/Edge expansion.
• Potential re-rating if management demonstrates AI-driven revenue growth rather than just AI bookings.

• Generative AI actually commoditizes consulting/IT services, compressing pricing, utilization, and revenue per consultant.
• Prolonged IT spending softness or a macro downturn pushes growth below the 3%-4% FY26 guidance range.
• The ~$9B M&A program could destroy value if deals are overpriced or poorly integrated.
• The stock's multiple could stay pinned at 13-15x even if fundamentals hold, limiting near-term upside.

Accenture is a high-quality, cash-generative franchise with 17% ROIC, negative accruals, a clean balance sheet, and a 4.7% dividend—selling at roughly half its historical P/E. The fundamental data does not support a bearish thesis yet, but the AI/consulting overhang is real enough that the market may keep the multiple capped. I view it as a reasonable long-term value/quality idea at current levels, but not an urgent buy after the sharp bounce; the honest call is neutral with a constructive bias.

Applied a 15.0x multiple to consensus forward EPS of $13.86, justified by ACN's 17% ROIC, negative accruals, stable FCF, and 4.7% dividend yield, while still respecting the structural AI-driven compression from its historical ~28x average. This yields a fair value of approximately $207.90, meaningfully above the $187.38 current price but below the 5-year average multiple.